MTOR and glioblastoma: GBM showed no response to everolimus (Chinnaiyan et al., 2018), which targets mTOR, but other drugs that target mTORC1/2 and cyclin-dependent kinases in the cell cycle machinery are under evaluation (Wen et al., 2020).